重组人血管内皮抑制素的作用机制及其在肿瘤治疗中的研究进展

Mechanism and research progress of recombinant human endostatin in carcinoma

重组人血管内皮抑制素为泛靶点类抗血管生成靶向药物,它的作用机制不仅包括在微观分子水平对内皮细胞表面蛋白表达及胞内信号通路的调控,还包括宏观上对肿瘤微环境的重塑,继而改善肿瘤的综合治疗疗效。研究表明抗血管生成治疗(如重组人血管内皮抑制素)与化疗、放疗、免疫治疗及其他靶向治疗等联合应用可发挥协同抗肿瘤作用。文章将对重组人血管内皮抑制素的作用机制、应用现状及其在不同肿瘤中的研究进展进行概括综述。

Recombinant human endostatin（rh-Endostatin）is an anti-angiogenic targeting drug with multi-targets. The mechanisms of rh-Endostatin include not only regulating the surface proteins of endothelial cells and intracellular signaling pathways at the microscopic molecular level,but also remodeling the microenvironment of tumors at macro level,and then improving the overall therapeutic effect of tumors. Numerous studies have shown that anti-angiogenic therapy（such as rh-Endostatin）can work together with chemo-radiotherapy,immunotherapy,and other targeted therapies to combat tumors. Our work will give a detailed review of the mechanisms and application of rh-Endostatin and its research progress in different tumors.